Tamam Bakchoul, MD

Medical Director
Center for Clinical Transfusion Medicine, University Hospital of Tübingen

Tamam Bakchoul studied Human Medicine in Lattakia, Syria and finished his Doctorate in medicine 2002. His Doctoral Thesis „Development of innovative methods for the detection of human platelet antibodies“ was completed at the Justus-Liebig-University Giessen, Germany in 2007. In 2015 Tamam Bakchoul habilitated in Transfusion Medicine at the University of Greiswald, Germany when he won a W1-Junior Professorship for Clinical Immunhematology and Haemostaseology. Since 2017 he has the W3-professorship for Transfusion Medicine at the Eberhard-Karls-University of Tübingen and is Medical Director of the Institute for Clinical and Experimental Transfusion Medicine at the University Hospital of Tübingen as well as the Medical Director of the Centrum for Clinical Transfusion Medicine.
Dr. Bakchoul is specialized in Transfusion Medicine and has an additional sup-specialization for Coagulation Disorder (Hemostaseology). His research work has a focus on platelet disorders and immune-mediated thrombotic thrombocytopenic. Tamam Bakchoul is a member of various Scientific Societies and work in the ISTH/SSC organization since 2012 and since 2020 as the chair of SSC „Platelet Immunology“.

Presentation(s):

• SSC 03.01 - Introduction

  Saturday, July 9, 2022
  2:30 PM – 2:35 PM

• SSC 03.10 - Conclusion

  Saturday, July 9, 2022
  4:25 PM – 4:30 PM

• PB0035 - Increased thrombus formation via procoagulant platelets in vaccine induced thrombotic thrombocytopenia (VITT)

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0036 - Clinical and serological follow up of VITT patients treated with heparin and alternative anticoagulation

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0096 - Sera from donors of COVID-19 convalescent plasma do not induce procoagulant phenotype in platelets

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0326 - Rapid immunoassay for platelet factor-4 in the diagnosis of vaccine-induced immune thrombotic thrombocytopenia after vaccination with ChAdOx1 nCoV-19

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0327 - Antibody-induced procoagulant platelets cause increased thrombus formation in heparin-induced thrombocytopenia

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• OC 33.1 - Functional studies on the interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia

  Monday, July 11, 2022
  10:45 AM – 11:00 AM

• PB0529 - Investigations of the impact of different bleeding disorders using a humanized in vivo mouse model

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0879 - Inhibition of apoptosis during cold storage of platelet concentrates better maintains both platelet functionality and survival

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• VPB0634 - Veno-occlusive disease in pediatric patients after stem cell transplant is associated with impaired fibrinolysis

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 69.5 - An integrative approach to diagnose heparin-induced thrombocytopenia: development, validation, and implementation of a multivariable prediction model

  Tuesday, July 12, 2022
  3:45 PM – 4:00 PM

• PB0993 - Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1100 - Vaccine Induced Immune Thrombocytopenia and Thrombosis (VITT) external quality assessment (EQA) scheme results and interpretations from a joint UKNEQAS BC, SSC and ECAT VITT Survey May 2021.

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1110 - Buffy-coat-derived megakaryocytes for monoclonal antibody immobilization of platelet antigens (MAIMA) assay

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1212 - Platelet desialylation status in adults with primary immune thrombocytopenia

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• OC 73.5 - Investigations to assess Impact of Syk-inhibition on antibody-mediated desialylation: novel implications on therapy for immune thrombocytopenia

  Wednesday, July 13, 2022
  11:15 AM – 11:30 AM